AXGT - Axovant Gene Therapies Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.52
+0.02 (+0.27%)
At close: 4:00PM EDT

7.52 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close7.50
Open7.38
Bid7.53 x 800
Ask7.57 x 800
Day's Range7.17 - 7.62
52 Week Range7.00 - 52.72
Volume232,168
Avg. Volume311,217
Market Cap171.305M
Beta (3Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-9.99
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.40
Trade prices are not sourced from all markets
  • Axovant Sciences Enters Oversold Territory
    Zacks3 days ago

    Axovant Sciences Enters Oversold Territory

    Axovant Sciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates
    Zacks3 days ago

    Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates

    Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.

  • GlobeNewswire4 days ago

    Axovant to Present at 2019 RBC Capital Markets Global Healthcare Conference

    BASEL, Switzerland, May 20, 2019 -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan.

  • NIH administers first clinical trial treatment for GM1 created by Auburn, UMass
    PR Newswire6 days ago

    NIH administers first clinical trial treatment for GM1 created by Auburn, UMass

    AUBURN, Ala., May 17, 2019 /PRNewswire/ -- The first clinical trial of a gene therapy treatment created through a research alliance between Auburn University and the University of Massachusetts has been administered in a child at the National Institutes of Health, or NIH, in Bethesda, Maryland. The NIH clinical trial is a significant milestone for GM1 gangliosidosis, a deadly disease with no approved treatment.

  • GlobeNewswire7 days ago

    Axovant Announces Dosing of First Patient in Clinical Program for AXO-AAV-GM1, a Novel Gene Therapy for GM1 Gangliosidosis

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced dosing of the first patient in a clinical study of AXO-AAV-GM1 (also known as AAV9-GLB1), an investigational gene therapy for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a progressive and fatal pediatric lysosomal storage disorder caused by mutations in the GLB1 gene leading to impaired production of the beta-galactosidase enzyme.

  • Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion
    Zacks10 days ago

    Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion

    Regeneron's (REGN) Eylea gets FDA approval for label expansion to include patients of all stages with diabetic retinopathy.

  • GlobeNewswire16 days ago

    Axovant Announces Reverse Share Split Effectiveness

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced that a reverse share split of its common shares on a 1-for-8 basis will become effective on May 7, 2019.  The shares will begin trading on the split-adjusted basis on the Nasdaq Global Select Market under the Company's existing trading symbol "AXGT" on May 8, 2019. The new CUSIP number following the reverse share split will be G0750W203. The reverse share split will reduce the number of common shares issued and outstanding from approximately 182.2 million common shares to approximately 22.8 million, based on shares outstanding as of March 31, 2019.

  • Markit17 days ago

    See what the IHS Markit Score report has to say about Axovant Sciences Ltd.

    Axovant Sciences Ltd NASDAQ/NGS:AXGTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for AXGT with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding AXGT are favorable, with net inflows of $687 million. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire24 days ago

    Axovant Announces Dosing of First Patient in Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, announced the dosing of the first patient of the second cohort in the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD in Parkinson’s disease patients. “We are pleased to begin enrolling additional patients in the SUNRISE-PD study at a higher dose level, following encouraging 3-month data from the first cohort,” said Dr. Gavin Corcoran, Axovant’s Chief Research and Development Officer. “We look forward to exploring the full clinical potential of AXO-Lenti-PD in patients with Parkinson’s disease, building upon the safety profile and improvements in motor symptoms that have been observed in 17 patients evaluated across the ProSavin and AXO-Lenti-PD programs.

  • Imagine Owning Axovant Gene Therapies (NASDAQ:AXGT) And Trying To Stomach The 91% Share Price Drop
    Simply Wall St.28 days ago

    Imagine Owning Axovant Gene Therapies (NASDAQ:AXGT) And Trying To Stomach The 91% Share Price Drop

    Axovant Gene Therapies Ltd. (NASDAQ:AXGT) shareholders should be happy to see the share price up 19% in the last quarter. But only the myopic could ignore the astounding decline over three years. The share price has sunk l...

  • GlobeNewswirelast month

    Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

    -Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and the AXO-AAV-GM2 program to be featured in oral presentations- -Preclinical data from AXO-AAV-GM1 program to.

  • Axovant (AXGT) Upgraded to Buy: What Does It Mean for the Stock?
    Zackslast month

    Axovant (AXGT) Upgraded to Buy: What Does It Mean for the Stock?

    Axovant (AXGT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) GALAPAGOS NV/S ...

  • GlobeNewswire2 months ago

    Axovant Announces Plan to Effect Reverse Share Split

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced that its Board of Directors and a majority of its shareholders have approved a reduction of issued and outstanding common shares on a 1-for-8 basis that is expected to become effective in May 2019. The reverse share split will reduce the number of common shares issued and outstanding from approximately 182.2 million common shares to approximately 22.8 million, based on shares outstanding as of March 31, 2019. The Company also noted the closing of the public offering of common shares in March 2019 for gross proceeds of $40 million with participation from leading institutional shareholders.

  • GlobeNewswire2 months ago

    Axovant Announces Clinical Updates from AXO-AAV-GM2 and AXO-Lenti-PD Studies

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced additional data and plans for the AXO-AAV-GM2 and AXO-Lenti-PD programs, which will be highlighted at the Company’s R&D day for investors and analysts.

  • ACCESSWIRE2 months ago

    Axovant Sciences Gene Therapy Showing Progress, Pipeline Review

    NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Here's Why Axovant Gene Therapies Dropped as Much as 16.6% Today
    Motley Fool2 months ago

    Here's Why Axovant Gene Therapies Dropped as Much as 16.6% Today

    The biopharma is wisely taking advantage of its lofty stock price to raise capital through a share offering.

  • GlobeNewswire2 months ago

    Axovant Sciences Announces Pricing of $40 Million Public Offering of Common Shares

    Axovant Sciences (AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 26,666,667 of its common shares at a price to the public of $1.50 per share. Gross proceeds to Axovant from the offering are expected to be approximately $40,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.  All of the common shares are being offered by Axovant. In connection with this offering, Axovant has granted the underwriters a 30-day option to purchase up to an additional 4,000,000 of its common shares on the same terms and conditions.  The offering is expected to close on March 18, 2019, subject to customary closing conditions.

  • GlobeNewswire2 months ago

    Axovant Sciences Announces Public Offering of Common Shares

    Axovant Sciences (AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of the common shares are being offered by Axovant. In connection with this offering, Axovant expects to grant the underwriters a 30-day option to purchase additional common shares in the offering on the same terms and conditions.

  • Benzinga2 months ago

    Axovant Shares Surge On Positive Results For Parkinson's, Tay-Sachs Gene Therapies

    Smaller gene therapy biotechs are taking the spotlight given the M&A interest surrounding them. One such gene therapy company saw its shares rallying by more than 30 percent Monday following the release ...

  • Here's Why Axovant Gene Therapies Rocketed Higher Today
    Motley Fool2 months ago

    Here's Why Axovant Gene Therapies Rocketed Higher Today

    Investors are excited about new clinical results suggesting the small-cap biopharma is on to something big.